Muschol, N. Et Al. 2018. ICV-administered BMN 250 (NAGLU-IGF2) is Well Tolerated and Reduces Heparan Sulfate Accumulation in the CNS of Subjects with Sanfilippo Syndrome Type B (MPS IIIB). 47th Annual Meeting of the Child-Neurology-Society (CNS) , (Illinois, United States Of America).

Muschol, N., Cleary, M., Couce, M., Harmatz, P., Lee, J., Lin, S. P., ... Okur, İ.(2018). ICV-administered BMN 250 (NAGLU-IGF2) is Well Tolerated and Reduces Heparan Sulfate Accumulation in the CNS of Subjects with Sanfilippo Syndrome Type B (MPS IIIB) . 47th Annual Meeting of the Child-Neurology-Society (CNS), Illinois, United States Of America

Muschol, N. Et Al. "ICV-administered BMN 250 (NAGLU-IGF2) is Well Tolerated and Reduces Heparan Sulfate Accumulation in the CNS of Subjects with Sanfilippo Syndrome Type B (MPS IIIB)," 47th Annual Meeting of the Child-Neurology-Society (CNS), Illinois, United States Of America, 2018

Muschol, N. Et Al. "ICV-administered BMN 250 (NAGLU-IGF2) is Well Tolerated and Reduces Heparan Sulfate Accumulation in the CNS of Subjects with Sanfilippo Syndrome Type B (MPS IIIB)." 47th Annual Meeting of the Child-Neurology-Society (CNS) , Illinois, United States Of America, 2018

Muschol, N. Et Al. (2018) . "ICV-administered BMN 250 (NAGLU-IGF2) is Well Tolerated and Reduces Heparan Sulfate Accumulation in the CNS of Subjects with Sanfilippo Syndrome Type B (MPS IIIB)." 47th Annual Meeting of the Child-Neurology-Society (CNS) , Illinois, United States Of America.

@conferencepaper{conferencepaper, author={N. Muschol Et Al. }, title={ICV-administered BMN 250 (NAGLU-IGF2) is Well Tolerated and Reduces Heparan Sulfate Accumulation in the CNS of Subjects with Sanfilippo Syndrome Type B (MPS IIIB)}, congress name={47th Annual Meeting of the Child-Neurology-Society (CNS)}, city={Illinois}, country={United States Of America}, year={2018}}